{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:22:19Z","timestamp":1791274939096,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T00:00:00Z","timestamp":1389830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11882-013-0418-0","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T06:57:34Z","timestamp":1389769054000},"source":"Crossref","is-referenced-by-count":38,"title":["Genotyping for Severe Drug Hypersensitivity"],"prefix":"10.1007","volume":"14","author":[{"given":"Eric","family":"Karlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,16]]},"reference":[{"issue":"7","key":"418_CR1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","volume":"42","author":"C Kongkaew","year":"2008","unstructured":"Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017\u201325.","journal-title":"Ann Pharmacother"},{"key":"418_CR2","doi-asserted-by":"crossref","unstructured":"Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay - a systematic review. Eur J Clin Pharmacol. 2013.","DOI":"10.1007\/s00228-013-1563-z"},{"issue":"12","key":"418_CR3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1345\/aph.10094","volume":"34","author":"DC Suh","year":"2000","unstructured":"Suh DC et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34(12):1373\u20139.","journal-title":"Ann Pharmacother"},{"issue":"7456","key":"418_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15\u20139.","journal-title":"BMJ"},{"issue":"11","key":"418_CR5","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","volume":"13","author":"R Pavlos","year":"2012","unstructured":"Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285\u2013306.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"418_CR6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1172\/JCI119505","volume":"100","author":"B Schnyder","year":"1997","unstructured":"Schnyder B et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest. 1997;100(1):136\u201341.","journal-title":"J Clin Invest"},{"issue":"8","key":"418_CR7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI3544","volume":"102","author":"MP Zanni","year":"1998","unstructured":"Zanni MP et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest. 1998;102(8):1591\u20138.","journal-title":"J Clin Invest"},{"issue":"4","key":"418_CR8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/intimm\/10.4.507","volume":"10","author":"MP Zanni","year":"1998","unstructured":"Zanni MP et al. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta + T cell clones. Int Immunol. 1998;10(4):507\u201315.","journal-title":"Int Immunol"},{"issue":"8","key":"418_CR9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","volume":"139","author":"WJ Pichler","year":"2003","unstructured":"Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683\u201393.","journal-title":"Ann Intern Med"},{"key":"418_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","volume":"52","author":"M Bharadwaj","year":"2012","unstructured":"Bharadwaj M et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401\u201331.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"418_CR11","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","volume":"26","author":"MA Norcross","year":"2012","unstructured":"Norcross MA et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26(11):F21\u20139. Using abacavir-treated HLA-B*57:01 B-cell lines, the authors demonstrated additional evidence that abacavir alters the quantity and quality of self-peptide loading into HLA-B*57:01.","journal-title":"AIDS"},{"issue":"6","key":"418_CR12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","volume":"129","author":"CY Wei","year":"2012","unstructured":"Wei CY et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562\u20139 e5. This article demonstrates a direct interaction of HLA molecules with drugs and provides a potential mechanism for HLA-associated drug hypersensitivity reactions. Supportive of altered peptide repertoire model for carbamazepine.","journal-title":"J Allergy Clin Immunol"},{"issue":"7404","key":"418_CR13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","volume":"486","author":"PT Illing","year":"2012","unstructured":"Illing PT et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554\u20138. Study supporting the altered peptide repertoire model for abacavir hypersensitivity. Abacavir associates with HLA-B*57:01 non-covalently and alters the shape and chemistry of the antigen-binding cleft. This leads to an altered repertoire of endogenous peptides binding HLA-B*57:01. The crystal structure of abacavir-MHC-peptide was resolved using an endogenous peptide. Preliminary evidence to support the altered peptide repertoire model for was also presented.","journal-title":"Nature"},{"issue":"25","key":"418_CR14","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","volume":"109","author":"DA Ostrov","year":"2012","unstructured":"Ostrov DA et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109(25):9959\u201364. Provided structural, biochemical and functional evidence for non-covalent interaction between abacavir and HLA-B*57:01 and the altered repertoire model for abacavir. A synthetic peptide was derived that binds to HLA-B*57:01 only in the presence of abacavir. The crystal structure of abacavir-MHC-peptide was resolved using this peptide.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"418_CR15","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1345\/aph.1E202","volume":"38","author":"AG Cutrell","year":"2004","unstructured":"Cutrell AG et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171\u20132.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"418_CR16","first-page":"222","volume":"11","author":"M Shapiro","year":"2001","unstructured":"Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read. 2001;11(4):222\u20136.","journal-title":"AIDS Read"},{"issue":"4","key":"418_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0149-2918(02)85132-3","volume":"24","author":"W Symonds","year":"2002","unstructured":"Symonds W et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24(4):565\u201373.","journal-title":"Clin Ther"},{"issue":"9308","key":"418_CR18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal S et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727\u201332.","journal-title":"Lancet"},{"issue":"9312","key":"418_CR19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","volume":"359","author":"S Hetherington","year":"2002","unstructured":"Hetherington S et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121\u20132.","journal-title":"Lancet"},{"issue":"2","key":"418_CR20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","volume":"5","author":"AR Hughes","year":"2004","unstructured":"Hughes AR et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5(2):203\u201311.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"418_CR21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","volume":"46","author":"M Saag","year":"2008","unstructured":"Saag M et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"418_CR22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568\u201379.","journal-title":"N Engl J Med"},{"issue":"15","key":"418_CR23","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/QAD.0b013e3283103ce6","volume":"22","author":"BR Schackman","year":"2008","unstructured":"Schackman BR et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025\u201333.","journal-title":"AIDS"},{"issue":"1","key":"418_CR24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","volume":"43","author":"A Rauch","year":"2006","unstructured":"Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99\u2013102.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"418_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11427-013-4438-8","volume":"56","author":"Y Guo","year":"2013","unstructured":"Guo Y et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci. 2013;56(2):119\u201324.","journal-title":"Sci China Life Sci"},{"issue":"6","key":"418_CR26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","volume":"28","author":"D Chessman","year":"2008","unstructured":"Chessman D et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28(6):822\u201332.","journal-title":"Immunity"},{"issue":"7","key":"418_CR27","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/eji.201142159","volume":"42","author":"J Adam","year":"2012","unstructured":"Adam J et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 2012;42(7):1706\u201316. Paper providing evidence that abacavir interacts with HLA-B*57:01 in a non-covalent and metabolism-independent fashion. Additionally, this study provided evidence that abacavir-reactive T-cell clones are dependent on the drug concentration, TCR avidity and level of HLA-B*57:01 molecules expressed on APCs.","journal-title":"Eur J Immunol"},{"issue":"5","key":"418_CR28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1517\/14740338.2012.705828","volume":"11","author":"SR Knowles","year":"2012","unstructured":"Knowles SR, Dewhurst N, Shear N. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767\u201378.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"418_CR29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134\u201343. First GWAS for carbamazepine in Europeans that identified an association with HLA-A*31:01 and individuals of northern European ancestry with various phenotypes of carbamazepine-induced hypersensitivity reactions. Although this study suggested an association between HLA-A*31:01 and carbamazepine SJS\/TEN in European populations, not all follow-up studies have supported this.","journal-title":"N Engl J Med"},{"issue":"6982","key":"418_CR30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung WH et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.","journal-title":"Nature"},{"issue":"3","key":"418_CR31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1533-2500.2011.00479.x","volume":"12","author":"K Kulkantrakorn","year":"2012","unstructured":"Kulkantrakorn K et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 2012;12(3):202\u20138.","journal-title":"Pain Pract"},{"issue":"6","key":"418_CR32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","volume":"75","author":"TY Mehta","year":"2009","unstructured":"Mehta TY et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75(6):579\u201382.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"418_CR33","first-page":"290","volume":"29","author":"SM Then","year":"2011","unstructured":"Then SM et al. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol. 2011;29(3):290\u20133.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"5","key":"418_CR34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","volume":"48","author":"CB Man","year":"2007","unstructured":"Man CB et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015\u20138.","journal-title":"Epilepsia"},{"issue":"6","key":"418_CR35","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","volume":"20","author":"Q Wang","year":"2011","unstructured":"Wang Q et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011;20(6):446\u20138.","journal-title":"Seizure"},{"issue":"9","key":"418_CR36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","volume":"67","author":"Y Zhang","year":"2011","unstructured":"Zhang Y et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011;67(9):885\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"418_CR37","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen P et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126\u201333.","journal-title":"N Engl J Med"},{"issue":"6","key":"418_CR38","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","volume":"128","author":"TM Ko","year":"2011","unstructured":"Ko TM et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266\u201376. Important in vitro study that establishes the essential role of the TCR in the mechanism behind SJS\/TEN and explains why some HLA-B*15:02 carriers are tolerant to carbamazepine.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"418_CR39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1346-8138.2011.01421.x","volume":"39","author":"K Mizumoto","year":"2012","unstructured":"Mizumoto K et al. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101. J Dermatol. 2012;39(9):791\u20132.","journal-title":"J Dermatol"},{"issue":"7","key":"418_CR40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","volume":"39","author":"H Niihara","year":"2012","unstructured":"Niihara H et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594\u2013601.","journal-title":"J Dermatol"},{"issue":"5","key":"418_CR41","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","volume":"20","author":"T Ozeki","year":"2011","unstructured":"Ozeki T et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034\u201341. GWAS that showed association with HLA-A*31:01 and carbamazepine-induced immunologically mediated adverse drug reactions in those of Japanese ancestry.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"418_CR42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.2012.189","volume":"92","author":"VL Yip","year":"2012","unstructured":"Yip VL et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012;92(6):757\u201365.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"418_CR43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","volume":"94","author":"U Amstutz","year":"2013","unstructured":"Amstutz U et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013;94(1):142\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"418_CR44","doi-asserted-by":"crossref","unstructured":"Ramasamy SN et al. Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012. Drug Saf. 2013.","DOI":"10.1007\/s40264-013-0084-0"},{"issue":"2","key":"418_CR45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","volume":"64","author":"RW Rundles","year":"1966","unstructured":"Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64(2):229\u201358.","journal-title":"Ann Intern Med"},{"issue":"11","key":"418_CR46","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007611-197911000-00004","volume":"72","author":"PG Lang Jr","year":"1979","unstructured":"Lang Jr PG. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72(11):1361\u20138.","journal-title":"South Med J"},{"issue":"5","key":"418_CR47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","volume":"20","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391\u20135.","journal-title":"Semin Dial"},{"issue":"1","key":"418_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000248097","volume":"179","author":"SH Chan","year":"1989","unstructured":"Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica. 1989;179(1):32\u20133.","journal-title":"Dermatologica"},{"issue":"11","key":"418_CR49","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"418_CR50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000102045","volume":"215","author":"T Dainichi","year":"2007","unstructured":"Dainichi T et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215(1):86\u20138.","journal-title":"Dermatology"},{"issue":"11","key":"418_CR51","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","volume":"9","author":"N Kaniwa","year":"2008","unstructured":"Kaniwa N et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617\u201322.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"418_CR52","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","volume":"19","author":"W Tassaneeyakul","year":"2009","unstructured":"Tassaneeyakul W et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704\u20139.","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"418_CR53","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","volume":"26","author":"JW Jung","year":"2011","unstructured":"Jung JW et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011;26(11):3567\u201372.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"418_CR54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","volume":"21","author":"HR Kang","year":"2011","unstructured":"Kang HR et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303\u20137.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"418_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99\u2013107.","journal-title":"Pharmacogenet Genomics"},{"key":"418_CR56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","volume":"6","author":"E Genin","year":"2011","unstructured":"Genin E et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"418_CR57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","volume":"13","author":"M Tohkin","year":"2013","unstructured":"Tohkin M et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60\u20139.","journal-title":"Pharmacogenomics J"},{"key":"418_CR58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","volume":"12","author":"R Somkrua","year":"2011","unstructured":"Somkrua R et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.","journal-title":"BMC Med Genet"},{"issue":"1","key":"418_CR59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01163.x","volume":"250","author":"YA Pompeu","year":"2012","unstructured":"Pompeu YA et al. The structural basis of HLA-associated drug hypersensitivity syndromes. Immunol Rev. 2012;250(1):158\u201366.","journal-title":"Immunol Rev"},{"issue":"6","key":"418_CR60","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","volume":"20","author":"RB Pollard","year":"1998","unstructured":"Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071\u201392.","journal-title":"Clin Ther"},{"issue":"7\u20138","key":"418_CR61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1345\/aph.19258","volume":"34","author":"M Gangar","year":"2000","unstructured":"Gangar M et al. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother. 2000;34(7\u20138):839\u201342.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"418_CR62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","volume":"19","author":"AM Martin","year":"2005","unstructured":"Martin AM et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19(1):97\u20139.","journal-title":"AIDS"},{"issue":"10","key":"418_CR63","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","volume":"25","author":"J Yuan","year":"2011","unstructured":"Yuan J et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25(10):1271\u201380. Genetic study investigating different clinical presentations of nevirapine hypersensitivity and reporting several new associations with specific HLA alleles.","journal-title":"AIDS"},{"issue":"4","key":"418_CR64","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","volume":"22","author":"ZG Vitezica","year":"2008","unstructured":"Vitezica ZG et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22(4):540\u20131.","journal-title":"AIDS"},{"issue":"2","key":"418_CR65","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/QAI.0b013e31827ca50f","volume":"62","author":"E Phillips","year":"2013","unstructured":"Phillips E et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e55\u20137. A class II allele DRB1*01:02 which is homologous to DRB1*01:01 is related to nevirapine-associated hepatitis in South African Black populations.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"418_CR66","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","volume":"20","author":"R Littera","year":"2006","unstructured":"Littera R et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20(12):1621\u20136.","journal-title":"AIDS"},{"issue":"2","key":"418_CR67","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","volume":"21","author":"H Gatanaga","year":"2007","unstructured":"Gatanaga H et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21(2):264\u20135.","journal-title":"AIDS"},{"issue":"6","key":"418_CR68","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1089\/aid.2011.0107","volume":"28","author":"S Gao","year":"2012","unstructured":"Gao S et al. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. AIDS Res Hum Retroviruses. 2012;28(6):540\u20133.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"418_CR69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","volume":"19","author":"S Chantarangsu","year":"2009","unstructured":"Chantarangsu S et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19(2):139\u201346.","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"418_CR70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/cir403","volume":"53","author":"S Chantarangsu","year":"2011","unstructured":"Chantarangsu S et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis. 2011;53(4):341\u20138.","journal-title":"Clin Infect Dis"},{"key":"418_CR71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","volume":"6","author":"S Likanonsakul","year":"2009","unstructured":"Likanonsakul S et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther. 2009;6:22.","journal-title":"AIDS Res Ther"},{"issue":"9","key":"418_CR72","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","volume":"56","author":"DF Carr","year":"2013","unstructured":"Carr DF et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis. 2013;56(9):1330\u20139. First study to associate HLA-C*04:01 with nevirapine-associated Stevens-Johnson Syndrome\/Toxic epidermal necrolysis in a Black African population.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"418_CR73","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03602532.2011.605790","volume":"44","author":"AK Daly","year":"2012","unstructured":"Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116\u201326.","journal-title":"Drug Metab Rev"},{"issue":"5","key":"418_CR74","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","volume":"117","author":"ML Hautekeete","year":"1999","unstructured":"Hautekeete ML et al. HLA association of amoxicillin-clavulanate\u2013induced hepatitis. Gastroenterology. 1999;117(5):1181\u20136.","journal-title":"Gastroenterology"},{"issue":"5","key":"418_CR75","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.47.5.717","volume":"47","author":"J O\u2019Donohue","year":"2000","unstructured":"O\u2019Donohue J et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717\u201320.","journal-title":"Gut"},{"issue":"6","key":"418_CR76","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2010.05.033","volume":"53","author":"PT Donaldson","year":"2010","unstructured":"Donaldson PT et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53(6):1049\u201353.","journal-title":"J Hepatol"},{"issue":"1","key":"418_CR77","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","volume":"141","author":"MI Lucena","year":"2011","unstructured":"Lucena MI et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338\u201347.","journal-title":"Gastroenterology"},{"issue":"4","key":"418_CR78","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.21324","volume":"44","author":"MI Lucena","year":"2006","unstructured":"Lucena MI et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850\u20136.","journal-title":"Hepatology"},{"issue":"7","key":"418_CR79","doi-asserted-by":"crossref","first-page":"e68111","DOI":"10.1371\/journal.pone.0068111","volume":"8","author":"C Stephens","year":"2013","unstructured":"Stephens C et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8(7):e68111.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"418_CR80","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","volume":"15","author":"R Olsson","year":"1992","unstructured":"Olsson R et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15(1\u20132):154\u201361.","journal-title":"J Hepatol"},{"issue":"1","key":"418_CR81","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2005.02370.x","volume":"60","author":"S Russmann","year":"2005","unstructured":"Russmann S et al. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol. 2005;60(1):76\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"418_CR82","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly AK et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816\u20139.","journal-title":"Nat Genet"},{"issue":"3","key":"418_CR83","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/QAD.0b013e32835ca9d5","volume":"27","author":"EJ Phillips","year":"2013","unstructured":"Phillips EJ, Mallal SA. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS. 2013;27(3):491\u20132.","journal-title":"AIDS"},{"issue":"10","key":"418_CR84","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","volume":"9","author":"PB Ferrell Jr","year":"2008","unstructured":"Ferrell Jr PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543\u20136.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"418_CR85","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","volume":"19","author":"EJ Phillips","year":"2005","unstructured":"Phillips EJ et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979\u201381.","journal-title":"AIDS"},{"issue":"9","key":"418_CR86","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0b013e3282f7cb60","volume":"22","author":"NH Shear","year":"2008","unstructured":"Shear NH et al. A review of drug patch testing and implications for HIV clinicians. AIDS. 2008;22(9):999\u20131007.","journal-title":"AIDS"},{"issue":"16","key":"418_CR87","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/00002030-200211080-00017","volume":"16","author":"EJ Phillips","year":"2002","unstructured":"Phillips EJ et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002;16(16):2223\u20135.","journal-title":"AIDS"},{"issue":"3","key":"418_CR88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1600-0536.2003.00065.x","volume":"48","author":"AY Lee","year":"2003","unstructured":"Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis. 2003;48(3):137\u20139.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"418_CR89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1440-0960.2012.00887.x","volume":"53","author":"AB Buyuktiryaki","year":"2012","unstructured":"Buyuktiryaki AB et al. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Australas J Dermatol. 2012;53(4):274\u20137.","journal-title":"Australas J Dermatol"},{"key":"418_CR90","doi-asserted-by":"crossref","unstructured":"Lin YT, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2012.","DOI":"10.1111\/j.1468-3083.2011.04418.x"},{"issue":"7","key":"418_CR91","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMc1105467","volume":"365","author":"EJ Phillips","year":"2011","unstructured":"Phillips EJ, Mallal SA. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med. 2011;365(7):672. author reply 673.","journal-title":"N Engl J Med"},{"issue":"12","key":"418_CR92","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","volume":"101","author":"AM Martin","year":"2004","unstructured":"Martin AM et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101(12):4180\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"418_CR93","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/135965350701200708","volume":"12","author":"E Hammond","year":"2007","unstructured":"Hammond E et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther. 2007;12(7):1027\u201332.","journal-title":"Antivir Ther"},{"issue":"5","key":"418_CR94","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.fpc.0000197468.16126.cd","volume":"16","author":"AM Martin","year":"2006","unstructured":"Martin AM et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006;16(5):353\u20137.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"418_CR95","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1089\/gtmb.2012.0115","volume":"16","author":"R Melis","year":"2012","unstructured":"Melis R et al. Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. Genet Test Mol Biomarkers. 2012;16(9):1111\u20134.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"17","key":"418_CR96","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","volume":"369","author":"FR Zhang","year":"2013","unstructured":"Zhang FR et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620\u20138.","journal-title":"N Engl J Med"},{"key":"418_CR97","doi-asserted-by":"crossref","unstructured":"Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E. Fever, rash and systemic symptoms: understanding the role of virus and HLA in cutaneous drug allergy. J Allerg Clin Immunol In Practice. 2014;2(1):21\u201333.","DOI":"10.1016\/j.jaip.2013.11.005"},{"issue":"1\u20132","key":"418_CR98","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","volume":"97","author":"SH Kim","year":"2011","unstructured":"Kim SH et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97(1\u20132):190\u20137.","journal-title":"Epilepsy Res"},{"issue":"12","key":"418_CR99","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","volume":"51","author":"N Kaniwa","year":"2010","unstructured":"Kaniwa N et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461\u20135.","journal-title":"Epilepsia"},{"issue":"2","key":"418_CR100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","volume":"51","author":"H Ikeda","year":"2010","unstructured":"Ikeda H et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51(2):297\u2013300.","journal-title":"Epilepsia"},{"issue":"3","key":"418_CR101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","volume":"11","author":"SI Hung","year":"2010","unstructured":"Hung SI et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349\u201356.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"418_CR102","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1607-551X(09)70045-2","volume":"25","author":"LC Lin","year":"2009","unstructured":"Lin LC et al. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci. 2009;25(2):82\u20136.","journal-title":"Kaohsiung J Med Sci"},{"issue":"7","key":"418_CR103","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","volume":"54","author":"YK Cheung","year":"2013","unstructured":"Cheung YK et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307\u201314.","journal-title":"Epilepsia"},{"issue":"12","key":"418_CR104","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","volume":"49","author":"C Locharernkul","year":"2008","unstructured":"Locharernkul C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087\u201391.","journal-title":"Epilepsia"},{"issue":"15","key":"418_CR105","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2217\/pgs.13.180","volume":"14","author":"N Kaniwa","year":"2013","unstructured":"Kaniwa N et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14(15):1821\u201331.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"418_CR106","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.10.54","volume":"11","author":"SH Kim","year":"2010","unstructured":"Kim SH et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879\u201384.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"418_CR107","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","volume":"7","author":"A Alfirevic","year":"2006","unstructured":"Alfirevic A et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7(6):813\u20138.","journal-title":"Pharmacogenomics"},{"issue":"8","key":"418_CR108","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","volume":"42","author":"JB Singer","year":"2010","unstructured":"Singer JB et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711\u20134.","journal-title":"Nat Genet"},{"issue":"3","key":"418_CR109","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","volume":"8","author":"A Kindmark","year":"2008","unstructured":"Kindmark A et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186\u201395.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"418_CR110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","volume":"29","author":"CF Spraggs","year":"2011","unstructured":"Spraggs CF et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667\u201373.","journal-title":"J Clin Oncol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-013-0418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-013-0418-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-013-0418-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T20:22:20Z","timestamp":1688934140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-013-0418-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,16]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1007\/s11882-013-0418-0","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,16]]},"article-number":"418"}}